Acquisition of Radioactive products (PLUVICTO and LUTATHERA)
Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYFALLS CHURCH, VA, 22042, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Set Aside

No Set aside used (NONE)

Original Source

https://sam.gov/workspace/contract/opp/43f4b2cc64a04b43a6f8c2494649d005/view
Timeline
    Description

    The Defense Health Agency (DHA) is planning to award a Firm-Fixed Price contract for the acquisition of radioactive products, specifically PLUVICTO and LUTATHERA, which are essential for imaging patients' diseases. These products must be U.S. FDA Approved and are to be supplied by Novartis Pharmaceuticals Corporation, the designated manufacturer. The total estimated cost for this procurement is $578,754.32, and interested parties are invited to express their interest and submit a capabilities statement by January 11, 2026, at 7:00 AM EST. For further inquiries, Malcolm Dodson can be contacted at malcolm.dodson.ctr@mail.mil or by phone at 703-275-6322.

    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Acquisition of Radioactive products (PLUVICTO and LUTATHERA)
    Currently viewing
    Special Notice
    Similar Opportunities
    Radiopharmaceutical Laboratory Services (RLS) MAMC
    Dept Of Defense
    The Department of Defense, through the Medical Readiness Contracting Office Pacific, is seeking qualified vendors to provide Radiopharmaceutical Laboratory Services for the Madigan Army Medical Center (MAMC) in Tacoma, Washington. The procurement includes a range of radiopharmaceuticals such as Technetium (Tc99m), Iodine (I-123, I-131), and related medical supplies, with a focus on FDA-approved materials and compliance with Joint Commission and USP 825 standards. These services are critical for supporting medical operations at the facility, ensuring timely access to essential radiopharmaceuticals for patient care. Interested vendors must submit their quotes by 10:00 AM PDT on January 15, 2026, to the primary contacts, Cindy Means and Scott Barr, with deliveries scheduled from January 31, 2026, to January 30, 2031.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--VA Phoenix and Tucson Radiopharmaceuticals IDIQ
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking qualified contractors to provide radiopharmaceuticals through a single-award Indefinite Delivery Indefinite Quantity (IDIQ) contract for the VA Phoenix and Tucson Healthcare Systems in Arizona. The procurement aims to identify potential sources capable of supplying a variety of radiopharmaceuticals, with daily ordering and next-day delivery requirements, ensuring compliance with federal and state regulations. This initiative is critical for supporting the healthcare needs of veterans, as these radiopharmaceuticals are essential for diagnostic and therapeutic procedures. Interested parties must submit their capabilities statements and relevant information by January 13, 2026, to Hestia Sim at Hestia.Sim@va.gov, as this request is for information and planning purposes only and does not constitute a solicitation.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is seeking quotations for pharmaceutical agents as part of the Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP) to support the Military Health System (MHS). This procurement aims to establish an effective pharmacy benefits program, ensuring the selection of clinically and cost-effective pharmaceutical agents for inclusion in the DoD Uniform Formulary, particularly focusing on oncological agents for myelofibrosis, such as Inrebic, Jakafi, Ojjaara, and Vonjo. Interested vendors must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025, and can direct inquiries to Tracy Banks or Stephanie Erpelding via their provided emails.
    6505--Radiopharmaceuticals RMR VAMC 5-year IDIQ
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for a five-year Indefinite Delivery Indefinite Quantity (IDIQ) contract for radiopharmaceuticals at the Rocky Mountain Regional VA Medical Center in Aurora, Colorado. The procurement aims to secure a reliable supply of various radiopharmaceuticals and related services, ensuring compliance with federal regulations and quality standards, while providing timely deliveries for medical diagnostic and therapeutic procedures. This contract has a guaranteed minimum value of $4,000 and a maximum ceiling of $3,000,000, with proposals due by 2:00 PM ET on January 20, 2026. Interested vendors should direct inquiries to Contract Specialist Chris Hollingsworth at Christopher.Hollingsworth2@va.gov.
    6505--RX - PYLARIFY (PIFLUFOLASTAT F 18 INJECTION) (NDC 71258-0022-01)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking sources for the procurement of Pylarify (Piflufolastat F 18 Injection), a radiopharmaceutical injection, to be delivered to VISN 2 Downstate Hospitals. This Sources Sought Notice aims to identify potential large and small businesses, including manufacturers and distributors, capable of providing functionally equivalent products. The procurement is essential for the VA's medical supply needs, particularly in the context of radiopharmaceutical applications in patient care. Interested parties must submit their responses, including firm details and contact information, via email to Aleta Jennette at Aleta.Jennette@va.gov by January 12, 2026, at 10 AM Eastern Time.
    6505--6505 - VISN 2 DOWNSTATE GENERAL RADIOPHARMACEUTICALS
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Network Contracting Office 2, is seeking qualified businesses to provide radiopharmaceuticals and related supplies for the VISN 2 Downstate Facilities located in New York and New Jersey. The procurement involves daily delivery of unit and bulk dose radiopharmaceuticals, quality control (QC) procedures, and miscellaneous supplies necessary for nuclear medicine diagnostic and therapeutic procedures at various VA Medical Centers. This opportunity is critical for ensuring the availability of essential medical products and services to support the health care needs of veterans. Interested parties must respond with their company information, socio-economic status, and a capability statement by January 14, 2026, at 15:00 Eastern Time, to Contracting Officer Paul Speedling at Paul.Speedling@va.gov.
    6505--Notice of Intent to Sole Source Procurement - Flyrcado (F18 Flurpiridaz) Injection
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Network Contracting Office 17, intends to award a sole source procurement contract for Flyrcado (flurpiridaz F-18) Injection to Medi-Physics, Inc. This procurement involves the acquisition of 990 units of the injection, which is critical for diagnostic imaging in the healthcare sector. The pricing for this contract is based on an existing agreement with GE Healthcare, which stipulates that orders must be placed through Medi-Physics as open market orders. Interested parties are encouraged to submit capability statements within seven days of this notice, after which the contract may be awarded to Cardinal Health if no comparable sources are identified. For further inquiries, contact Contract Specialist Vance Farrell at vance.farrell@va.gov or by phone at 210-694-6379.
    Ondansetron Orally Disintegrating Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    TRICARE Pharmacy Program RFI
    Dept Of Defense
    The Defense Health Agency (DHA) is conducting a Request For Information (RFI) for its next-generation TRICARE Pharmacy Program (TPharm) contract, aimed at gathering industry feedback to inform the program's requirements and design. The RFI focuses on key areas such as pharmacy benefit administration, mail order pharmacy fulfillment, enhanced care programs, and operational barriers affecting vendor participation in federal pharmacy contracts. This program is crucial as it serves over 9.6 million beneficiaries and integrates various pharmacy services, including retail and mail order options. Interested parties are encouraged to submit their responses via email to dha.buckley.ad-spt-cae.mbx.tpharm6@health.mil by January 30, 2026, at 12:00 pm MST, as the DHA seeks to utilize this information for market research purposes.